FDA Archives - Journal of Psychiatry Reform

Agomelatine: is it really a firstline drug?

March 25, 2018,
0Comments

Vol 3 #2 March 2018 Agomelatine is listed as a firstline medication for the treament of depression in a number of guidelines including Canadian Guidelines. This is the case eventhough Agomelatine is not approved for use in Canada..

Posted by Editor JPR
Posted in Abstracts,Brief Review

Should Canadian patients look forward to aducanumab for Alzheimer disease?

September 12, 2021,
0Comments

Journal of Psychiatry Reform Vol 10 #12 This is an Open Access article from CMAJ distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence. Open Access Should Canadian patients look forward to aduca..

Posted by Alan Eppel
Posted in Creative Commons Republished,Editorials & Commentary